Abstract Traumatic brain injury (TBI) results in severe neurological impairments without effective treatments. Inflammation appears to be an important contributor to key pathogenic events such as secondary brain injury following TBI and therefore serves as a promising target for novel thera- 
Introduction
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity with a lack of effective treatments. TBI can Liu Yang and Zhijia Liu contributed equally to this work.
* Halina Offner offnerva@ohsu.edu * Minshu Li minshuli2012@163.com often result in long-term physical and cognitive deficits that involve primary and secondary injuries. The primary injury occurs at the moment of TBI, characterized by the disruption of blood brain barrier and blood vessels that contribute to brain edema (McKee and Lukens 2016; Pop and Badaut 2011) . This primary injury precedes downstream events contributing to a secondary injury cascade that includes the activation of brain-resident microglia and astrocytes and recruitment of peripheral immune cells into the brain (Kumar and Loane 2012; McKee and Lukens 2016; Raghupathi 2004; Ramlackhansingh et al. 2011 ). The inflammatory responses may start minutes after TBI onset and persist for weeks to months (Kumar and Loane 2012; McKee and Lukens 2016; Raghupathi 2004; Ramlackhansingh et al. 2011) . As a result, these immune components may promote cell death during the early phase after TBI impact and contribute to subsequent neurological impairments during the later stage (Kumar and Loane 2012; McKee and Lukens 2016; Raghupathi 2004; Ramlackhansingh et al. 2011) . Thus, targeting inflammation after TBI may serve as a promising strategy for the development of novel therapy (Corps et al. 2015) . The human leukocyte antigen (HLA)-DRα1 domain linked to mouse (m)MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct that can inhibit neuroantigen-specific T cells and block the binding of the cytokine/chemokine, macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages Meza-Romero et al. 2014; Wang et al. 2016) . Our recent studies have demonstrated the benefit of DRα1-MOG-35-55 in animal models of multiple sclerosis (experimental autoimmune encephalomyeliltis, EAE) and ischemic stroke (middle cerebral artery occlusion, MCAO). The current study aims to evaluate the therapeutic effect of DRα1-MOG-35-55 on functional outcomes, lesion volume and immune changes in the periphery and CNS in a mouse model of TBI.
Materials and methods

Animals
Male C57BL/6 mice (7-8 weeks old, 20-25 g body weight) were housed in animal facilities at Tianjin Neurological Institute (Tianjin, China) under standardized light-dark cycle, and provided with access to food and water. All animal experiments were performed in accordance with the institutional animal care guidelines approved by the Chinese Small Animal Protection Association. All animal studies were approved by the Animal Care and Use Committees of Tianjin Neurological Institute. Animals were randomly assigned to experimental groups. The experimental groups were as follows: FPI + vehicle and FPI + DRα1-MOG-35-55.
Induction of fluid percussion injury (FPI) in mice
The mice were anesthetized with 10% chloral hydrate (3 mg/ kg, intraperitoneal injection), cleaned and shaved, then placed in a stereotaxic instrument with an attachment for mouse surgery (Stoelting, Inc., IL, USA). A 2 mm hole was drilled, with dura intact, in the skull over the left parietal cortex (anteroposterior: +1.5 mm; medio-lateral: −1.2 mm). A 12-16 ms FPI was delivered at a pressure of 1.3-1.5 atm. After injury, the scalp incision was closed with interrupted 4-0 silk sutures. After surgery, mice were treated immediately with Vehicle or DRα1-MOG-35-55 by subcutaneous injection and daily thereafter for 9 consecutive days in housing with a 12-h light-dark cycle with food and water.
DRα1-MOG-35-55 cloning, production and purification Cloning, production, and purification of the DRα1-mMOG-35-55 construct have been described previously (MezaRomero et al. 2014) . Briefly, DRα1-mMOG-35-55 was designed as a single gene joining the mouse (m)MOG-35-55-encoding DNA sequence upstream of the HLA-DRα1 domain with a flexible linker (containing a thrombin cleavage site) between both elements. This single exon was cloned between the NcoI and XhoI restriction sites of the pET21d(+) vector, expressed in Escherichia coli, and the protein purified following standard purification techniques including anion exchange and size exclusion chromatography in the presence of 6 M urea. Protein was refolded after extensive dialysis in 20 mM Tris, pH 8.5, then concentrated to 1 mg/ml and flash frozen.
DRα1-MOG-35-55 administration
After FPI surgery, mice were randomly divided into two groups, one receiving 0.1 ml (100 μg) DRα1-MOG-35-55, the other receiving 0.1 ml Vehicle (5% dextrose in Tris-HCl, pH 8.5) by subcutaneous injection. DRα1-MOG-35-55 or Vehicle was administrated by s.c. injection immediately after FPI and was given on 9 consecutive days until the experiment ended. Both Vehicle and DRα1-MOG-35-55 treated mice were evaluated for neurological deficits and lesion size using histopathological staining on days 1, 3, 7 and 10. On day 3 after FPI, brain, spleen and blood were harvested for analysis of immune cell counts.
Neurological assessment
Neurological deficits were assessed using the modified Neurological Severity Score (mNSS) and corner turning tests at day 1, day 3, day 7 and day 10 after FPI by at least two investigators blinded to the treatments of FPI mice in each experiment. The mNSS rates neurological functioning and includes a composite of motor, sensory, reflex and balance tests. The corner turning test was used to assess sensorimotor and postural asymmetries. Each mouse being tested was allowed to enter a corner with an angle of 30 degrees and was required to turn either to the left or the right to exit the corner. This was repeated and recorded 10 times, with at least 5 min between trials, and the percentage of left turns out of total turns was calculated.
Lesion size measurement
Lesion volume was measured as previously described (Basrai et al. 2016; Meng et al. 2014; Tobin et al. 2014) . At day 1, 3, 7 or 10 after surgery, mice were transcardially perfused with PBS, followed by 4% paraformaldehyde to fix the brain tissue. After embedding with paraffin, serial 6 μm thick sections were cut through the injury site (bregma −1.5 mm to 1.50 mm). For each mouse, every 20th brain section (120 μm apart,~25 sections per brain) were collected for Hematoxylin and Eosin (H&E) staining. To determine lesion area of each slice from H&E, bright field images at 4× magnification were obtained of the lesion site, and two investigators blinded to the experiment calculated the lesion area by tracing damaged or abnormal looking tissue in the ipsilateral cortex using Image J 1.38 (National Institutes of Health, Bethesda, MD, USA). The down boundary of the lesion outline was determined by drawing the area in which the immune cell infiltration was observed, as previously described (Basrai et al. 2016) . For upper boundary of the lesion area, we outlined the expanse of the lesion using a mouse atlas (Tobin et al. 2014; Tsukano et al. 2016) . In order to confirm superficial lesion measurements using a digital caliper, we assessed the margins of the lesion in the anterior posterior plane. The lesion volumes were computed by integrating the lesion area of each slice measured at each coronal level and the distance between two sections.
Flow cytometry of brain, spleen and blood
At day 3 after FPI, brains and spleens were harvested and homogenized with 40 μm nylon cell strainers (Becton Dickinson, Franklin Lakes, NJ, USA) in PBS. Cell suspensions were cetrifuged at 2000 rpm for 5 min, and cell pellets were collected. Thereafter, 5 ml of 70% Percoll solution (GE Healthcare Bio Science AB, Uppsala, Sweden) were used to resuspend the brain cell pellet, and a 30% Percoll solution was overlaid. The gradient was centrifuged at 2000 rpm for 30 min at room temperature. Single cells in the interface between 30% and 70% Percoll were collected for antibody staining. Cells were diluted to 1 × 10 6 cells in 100 μl PBS solution with 1% BSA and stained for antibodies and isotype control. For splenocytes, erythrocytes were removed using 1 X RBC lysis buffer (eBioscience, Inc. San Diego, CA USA) as indicated in the instruction manual. Briefly, the cell pellet was resuspended in 5 ml of 1X RBC lysis buffer per spleen and incubated for 5 min at room temperature. Thereafter, 30 ml 1×PBS were added to stop the reaction. After centrifugation, the cell pellet was resuspended in 1xPBS solution for cell staining. For blood samples, mononuclear cells were isolated from the whole-blood of angular vein specimens and stained with fluorescent-labeled antibodies. All antibodies were purchased from Biolegend (San Diego, CA, USA) unless otherwise indicated, and the staining protocol followed the manual's instructions. The following antibodies for the flow expriment were used: CD45-Pecy7, CD11b-Percp, CD86-PE, CD206-FITC and CD74-APC. Fluorescence minus one (FMO) controls were stained, respectively. Flow cytometry data were obained on C6 (BD Bioscience, San Jose, CA, USA) and analyzed by Flow Jo version 7.6.1 (Informer Technologies, Walnut Creek, CA,USA).
Statistical analysis
All data are shown as mean ± SEM. Statistical analyses were performed using GraphPad 6.0 software. Two-tailed unpaired Student's t-test was used to determine significance of differences between two groups. Two-way ANOVA with multiple comparisons followed by the Bonferroni post hoc test were used for comparisons of multi-group data. P values ≤0.05 were considered significant.
Results
DRα1-MOG-35-55 attenuates neurodeficits and lesion volume in FPI mice
To assess the therapeutic effects of DRα1-MOG-35-55 after TBI, we measured neurological impairment scores and lesion volumes in mice subjected to fluid percussion injury (FPI). Mice received nine daily s.c. injections of 100 μg DRα1-MOG-35-55 or vehicle starting immediately after FPI (Fig. 1a) and were assessed intermitantly and 24 h after after the final treatment (day 10) using the modified Neurological Severity Score (mNSS) and the Corner Turning test. DRα1-MOG-35-55 treatment significantly reduced both neurodeficit measures (Fig. 1b-c) as well as lesion volumes (Fig. 2a-b) at all time points measured after TBI compared to vehicle controls. (Fig. 3a-b) , with predominant effects on CD11b + CD45 hi macrophages/ activated microglia (Fig. 3c) (Fig. 3d) (Fig. 3e) . (Fig. 4a-d Fig. 5a-d) .
Discussion
This study provides the first evidence that DRα1-MOG-35-55 treatment improves the outcome of TBI. Our results demonstrate that daily s.c. administration of DRα1-MOG-35-55 can significantly enhance functional outcomes, reduce brain lesion size, block infiltration of CD11b + cells into the injured brain, and promote an anti-inflammatory phenotype in activated CD11b + CD45
hi cells that infiltrate from the periphery or that result from local activation of resident CD11b + CD45 int microglia after TBI. These changes observed in the injured brain were in stark contrast with increased numbers of activated monocytes in the blood and the lack of any demonstrable changes in the spleen.
Recombinant T-cell receptor (TCR) ligands (RTL) are molecular constructs comprised of covalently linked α1 and β1 domains of MHC II molecules with an attached antigenic peptide (Pan et al. 2014; Zhu et al. 2015; Zhu et al. 2014) . Unlike four-domain MHC II molecules that induce T cell activation, RTLs are partial agonists of TCR and can deviate autoreactive T cell responses towards an anti-inflammatory phenotype (Burrows et al. 2001; Wang et al. 2003) . Moreover, RTL constructs can block binding and downstream signaling of the cytokine/chemokine, macrophage migration inhibitory factor (MIF) through its CD74 receptor on monocytes and macrophages (Vandenbark et al. 2013 ) (featured on Fig. 3 DRα1-MOG-35-55 treatment reduces activation of CD11b + CD45hi cells in brain after TBI. TBI was induced in C57BL/6 mice by FPI. Immediately after FPI, mice received a subcutaneous injection of DRα1-MOG-35-55 (100 μg in 0.1 ml) or Vehicle. Treatment was continued daily until day 3 after TBI. a The flow gating strategy for microglia (CD11b + CD45 int ), brain-infiltrating macrophages/activated microglia (CD11b + CD45 hi ), and their surface expression of CD74, CD86 and CD206 at day 3 after TBI. b Bar graph shows total numbers of microglia and brain-infiltrating macrophages per brain at day 3 after TBI in mice receiving DRα1-MOG-35-55 or Vehicle. c Bar graph shows total numbers of microglia or brain-infiltrating macrophages per brain at day 3 after TBI in mice receiving DRα1-MOG-35-55 or Vehicle. d Bar graph shows the expression of CD74 on microglia or brain-infiltrating macrophages at day 3 after TBI in mice receiving indicated treatments. In b-d, n = 10 for Vehicle group; n = 11 for DRα1-MOG-35-55 group. e Bar graph shows the expression of CD86 or CD206 in microglia at day 3 after TBI in mice receiving indicated treatments. n = 7 mice per group. *p < 0.05, **p < 0.01. Data are presented as mean ± SEM MDLinx.com;). It was previously demonstrated that neurodegeneration after TBI is dependent upon CD74 expression on antigen presenting cells (Tobin et al. 2014) . RTL treatment of stroke has been shown to inhibit brainreactive T cells without inducing general immunosuppression (Dziennis et al. 2011) . Previous studies demonstrated that RTL treatment can protect against EAE and ischemic brain injury in mice (Dziennis et al. 2011; Pan et al. 2014; Subramanian et al. 2009; Zhu et al. 2015; Zhu et al. 2014) However, the clinical translation of RTL for treatment of acute thrombolytic or TBI events is restricted by the requirement for rapid matching of recipient MHC II with the β1 domains of the RTL construct. Thus, we developed a second generation partial MHC construct, DRα1-MOG-35-55 that was shown to reverse EAE (Meza-Romero et al. 2014) as well as treat ischemic brain injury after transient MCAO (Benedek et al. 2014) . Like RTLs, DRα1-MOG-35-55 can also bind with high affinity to CD74 that we show here to be increased in the CNS of mice after TBI. We further showed that DRα1-MOG-35-55 treatment not only reduced the influx of T cells into the ischemic brain, but also shifted microglia/macrophage polarization toward a beneficial M2-like phenotype (increased expression of CD206). These findings suggest that DRα1-MOG-35-55 may thus act as a competitive inhibitor of MIF binding to CD74 and block downstream chemotactic and inflammatory activities (Meza-Romero et al. 2016) . Such mechanisms could account for the clinical and histological improvement after treatment with DRα1-MOG-35-55 of mice after TBI. Because the DRα1 domain is expressed in all humans, DRα1-MOG-35-55 treatment does not require HLA screening of potential recipients and could be administered immediately after TBI in human subjects.
The DRα1-MOG-35-55 construct was initially developed as a therapy for the MOG-35-55 peptide-induced murine model of multiple sclerosis, but it was also found to be highly effective for treatment of ischemic stroke and methamphetamine addiction in which T cell involvement is less clear. However, these inflammatory CNS conditions have in common increases in brain infiltrating CD11b
high macrophages (Benedek et al. 2014; Meza-Romero et al. 2014; Wang et al. 2016 ). DRα1-MOG-35-55 treatment has been shown to inhibit the infiltration of both T cells and CD11b + CD45 high macrophages in EAE and MCAO (Benedek et al. 2014; Meza-Romero et al. 2014; Wang et al. 2016) , and we observed the same phenomenon for macrophage migration inhibition in the current study using a mouse TBI model. However, while the infiltration of CD11b + CD45
high macrophages was reduced after DRα1-MOG-35-55 treatment, general T cell responses were largely unaltered (data not shown). This result was not surprising, since involvement of brain specific T cells has not yet been established in TBI.
It is also noteworthy that DRα1-MOG-35-55 treatment increased the total immune cell numbers in blood similar to what was reported earlier in the spleens of mice with EAE and MCAO. In EAE, spleen cell numbers increased after immunization to induce EAE and increased further with treatment (Meza-Romero et al. 2014) . In MCAO, vessel occlusion reduced spleen cell numbers by~90%, but again, treatment partially restored spleen cell numbers (Benedek et al. 2014) . Our current data in TBI indicate minimal impact of DRα1-MOG-35-55 on CD11b + cells in spleen, but a near doubling of total cells and CD74-expressing CD11b + cells in blood. In contrast, DRα1-MOG-35-55 treatment of TBI strongly inhibits the activation and recruitment of brain-infiltrating CD11b + CD45
hi cells and their expression of CD74, as well as reduced expression of the co-stimulatory CD86 molecule but enhanced expression of the anti-inflammatory M2 marker, CD206, on CD11b + CD45 int microglial cells within the CNS. These findings suggest that DRα1-MOG-35-55 binding to CD74 results in blockade of MIF activity that prevents activation and recruitment of circulating CD11b + cells into the injured brain after TBI and enhancement of M2-like microglial activity within the CNS.
In summary, this study shows the therapeutic efficacy of DRα1-MOG-35-55 in a mouse model of TBI. Considering the potency of DRα1-MOG-35-55 to reduce brain injury and neurodeficits after FPI impact, as well as its ability to provide benefit across MHC barriers, it is anticipated that there may be long-term benefit for TBI of continued intermittent treatment with DRα1-MOG-35-55.
